The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Genentech; Inovio Pharmaceuticals; Janssen; Lilly; Merck; NCCN; Nektar; Seagen
Research Funding - BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Ari David Baron
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - AstraZeneca; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Roche
Other Relationship - Bayer (I)
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Horizon Pharma; Incyte; Inovio Pharmaceuticals; Janssen; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst); US Patent No: 15/226,474 files on 7/1/15 (Inst)
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Jens Bedke
Consulting or Advisory Role - Astellas Oncology; AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; MSD; Nektar; Novartis; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb (I); Eisai; EUSA Pharma; Ipsen; MSD; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Bayer; Cardinal Health; Castle Biosciences; Eisai; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech; TTC Oncology
Travel, Accommodations, Expenses - Newlink Genetics
 
Marc-Oliver Grimm
Honoraria - Amgen; Apogepha; Astellas Pharma; AstraZeneca; Bayer Health; Bristol-Myers Squibb; Hexal; Hexal; Intuitive Surgical; Ipsen; Janssen-Cilag; Medac; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi/Aventis; Sanofi/Aventis
Consulting or Advisory Role - Amgen; Apogepha; AstraZeneca; Bayer Health; Bristol-Myers Squibb; Intuitive Surgical; Ipsen; Janssen-Cilag; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi
Research Funding - Bristol-Myers Squibb (Inst)
 
Sergio Bracarda
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Janssen Oncology; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Astellas Pharma; Exelixis/Ipsen; Ipsen; Novartis; Pfizer; Roche
 
Margitta Retz
No Relationships to Disclose
 
Chikara Ohyama
No Relationships to Disclose
 
Gary Grossfeld
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sandra Collette
Employment - Bristol-Myers Squibb
 
Padmanee Sharma
Stock and Other Ownership Interests - Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Forty Seven; Forty Seven (I); Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Jounce Therapeutics; Jounce Therapeutics (I); Marker Therapeutics; Marker Therapeutics (I); Neon Therapeutics; Neon Therapeutics (I); Oncolytics; Polaris; Polaris (I); TapImmune Inc.; TapImmune Inc. (I); Tvardi Therapeutics (I)
Consulting or Advisory Role - Amgen (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); Bristol-Myers Squibb (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Forty Seven; Forty Seven (I); Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Jounce Therapeutics; Jounce Therapeutics (I); Marker Therapeutics; Marker Therapeutics (I); Merck; Merck (I); Neon Therapeutics; Neon Therapeutics (I); Oncolytics; Pieris Pharmaceuticals; Polaris; Polaris (I); TapImmune Inc.; TapImmune Inc. (I); Tvardi Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792